Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CTSC | P53634 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2742286 | 1.00 | KMT2A (0.55) | KMT2ACTSCMEN1XIAPGAA | |
| SCHEMBL12240253 | 1.00 | KMT2A (0.55) | KMT2ACTSCMEN1XIAPGAA | |
| SCHEMBL15623811 | 0.88 | FNTA (0.52) | KMT2ACTSCMEN1POLB | |
| SCHEMBL8549002 | 0.87 | SPHK1 (0.57) | KMT2AMMP8MMEEGFRSRC | |
| SCHEMBL8251354 | 0.85 | SPHK1 (0.51) | KMT2ACTSCMEN1ANPEP | |
| SCHEMBL1697377 | 0.84 | MMP8 (0.53) | KMT2AGAAMMP8MMEEGFR | |
| SCHEMBL7413310 | 0.84 | ALPI (0.61) | KMT2ACTSCXIAPMMP8MME | |
| SCHEMBL5653978 | 0.84 | MMP8 (0.53) | KMT2AGAAMMP8MMEEGFR | |
| SCHEMBL3114367 | 0.84 | ALPI (0.61) | KMT2ACTSCXIAPMMP8MME | |
| SCHEMBL47278 | 0.84 | MMP8 (0.53) | KMT2AGAAMMP8MMEEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771317-B2 | Process for preparing lacosamide and related compounds | CAMBREX KARLSKOGA AB (SE) | 2017-09-26 | — | — | US | disclosed |
| US-20150299105-A1 | NEW PROCESS | CAMBREX KARLSKOGA AB (SE) | 2015-10-22 | — | — | US | disclosed |
| US-8957252-B2 | Process for preparation of lacosamide and some N-benzyl-propanamide intermediate derivatives | INDOCO REMEDIES LIMITED (IN) | 2015-02-17 | — | — | US | disclosed |
| US-8853453-B2 | Processes for reducing impurities in lacosamide | RANBAXY LABORATORIES LIMITED (IN) | 2014-10-07 | — | — | US | disclosed |
| US-8829226-B2 | Lacosamide intermediate compound, preparation method thereof and use thereof | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD (CN) | 2014-09-09 | — | — | US | disclosed |
| US-20130204042-A1 | PROCESSES FOR REDUCING IMPURITIES IN LACOSAMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2013-08-08 | — | — | US | disclosed |
| US-20130123522-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LIMITED (IN) | 2013-05-16 | — | — | US | disclosed |
| US-20130085304-A1 | PROCESSES FOR PREPARATION OF POLYMORPHIC FORMS OF LACOSAMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2013-04-04 | — | — | US | disclosed |
| US-20130066102-A1 | LACOSAMIDE INTERMEDIATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD (CN) | 2013-03-14 | — | — | US | disclosed |
| US-8378142-B2 | Intermediate compounds and their use in preparation of lacosamide | RANBAXY LABORATORIES LIMITED (IN) | 2013-02-19 | — | — | US | disclosed |
| US-20120283466-A1 | LACOSAMIDE INTERMEDIATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2012-11-08 | — | — | US | disclosed |
| US-8093426-B2 | 2-tritylamino-3-(hydroxy or methoxy)propionic acid, or corresponding benzylamide thereof as chemical intermediate; chirally pure lacosamide; high purity | RANBAXY LABORATORIES LIMITED (IN) | 2012-01-10 | — | — | US | disclosed |
| US-20120004452-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2012-01-05 | — | — | US | disclosed |
| US-20120004462-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299105-A1 | NEW PROCESS | SLC6A11, SLC6A1, SCN11A | KMT2A 1845/4885CTSC 1080/4885MEN1 4125/4885 |
| US-20130204042-A1 | PROCESSES FOR REDUCING IMPURITIES IN LACOSAMIDE | HEXA, NPEPPS, RNPEP | KMT2A 294/4885CTSC 1715/4885MEN1 3458/4885 |
| US-20120004452-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | HDAC2, HDAC5, SCN5A | KMT2A 178/4885CTSC 1854/4885MEN1 580/4885 |
| US-20130066102-A1 | LACOSAMIDE INTERMEDIATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | IDH3A, CACNA1C, DDC | KMT2A 723/4885CTSC 234/4885MEN1 3819/4885 |
| US-20130123522-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | LPXN, CACNA1B, PMP22 | KMT2A 792/4885CTSC 1237/4885MEN1 2456/4885 |
| US-20120283466-A1 | LACOSAMIDE INTERMEDIATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | IDH3A, CACNA1C, DDC | KMT2A 723/4885CTSC 234/4885MEN1 3819/4885 |
| US-20120004462-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | HDAC2, HDAC5, SCN5A | KMT2A 178/4885CTSC 1854/4885MEN1 580/4885 |
| US-20130085304-A1 | PROCESSES FOR PREPARATION OF POLYMORPHIC FORMS OF LACOSAMIDE | BDNF, FKBP1B, SCN5A | KMT2A 2332/4885CTSC 510/4885MEN1 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.